Evidence map›Paper›PMID 29843633›Full record

ArticleBMC cancer2018

Changes in ovarian cancer survival during the 20 years before the era of targeted therapy.

Jung-Yun Lee, Sunghoon Kim, Young Tae Kim, Myong Cheol Lim, Boram Lee, Kyu-Won Jung, Jae Weon Kim, Sang-Yoon Park, Young-Joo Won

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 1 pooled it
12.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 1 synthesis or guideline pooled it, 114 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Jung-Yun LeeDepartment of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, South Korea.
Sunghoon KimDepartment of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, South Korea.
Young Tae KimDepartment of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, South Korea.
Myong Cheol LimGynecologic Cancer Branch & Center for Uterine Cancer, National Cancer Center, Goyang, South Korea.
Boram LeeCancer Registration and Statistics Branch, National Cancer Center, Goyang, South Korea.
Kyu-Won JungCancer Registration and Statistics Branch, National Cancer Center, Goyang, South Korea.
Jae Weon KimDepartment of Obstetrics and Gynecology, Seoul National University College of medicine, Seoul, South Korea.
Sang-Yoon ParkGynecologic Cancer Branch & Center for Uterine Cancer, National Cancer Center, Goyang, South Korea.
Young-Joo WonCancer Registration and Statistics Branch, National Cancer Center, Goyang, South Korea. astra67@ncc.re.kr.
National Cancer Center · KRYonsei University · KRSeoul National University · KR

Funding

National Cancer Center NCC-1610200Yonsei University College of Medicine 2017-32-0033
6 · The paper itself

Abstract

backgroundThe survival of patients with ovarian cancer has improved because of surgery and chemotherapy. This study aimed to estimate the changes in survival rates among Korean women with ovarian cancer prior to the introduction of targeted therapy for ovarian cancer.

methodsData were obtained from the Korea Central Cancer Registry regarding patients who were diagnosed with epithelial ovarian cancer between 1995 and 2014. The relative survival rates were calculated for 5-year periods using the Ederer II method. Cox proportional hazard models were created to assess the associations of demographic and clinicopathological factors with ovarian cancer survival.

resultsDuring the study period, 22,880 women were diagnosed with epithelial ovarian cancer. The 5-year relative survival rate improved from 57.2% during 1995-1999 to 63.8% during 2010-2014 (P < 0.001). Survival outcomes improved between 1995 and 1999 and 2010-2014 for the serous and endometrioid carcinoma subtypes (P < 0.001). However, no improvements were observed for the mucinous and clear cell carcinoma subtypes (P = 0.189 and P = 0.293, respectively). Multivariate analysis revealed that younger age, early stage, recent diagnosis, primary surgical treatment, and non-serous histological subtype were favorable prognostic factors.

conclusionSurvival outcomes have improved for serous and endometrioid epithelial ovarian cancer in the last 20 years. However, no improvement was observed for patients with mucinous and clear cell carcinoma subtypes.

Indexed as

AdenocarcinomaAdultAge FactorsCarcinoma, Ovarian EpithelialFemaleHumansMiddle AgedNeoplasm StagingOvarian NeoplasmsOvaryProportional Hazards ModelsRepublic of KoreaRetrospective StudiesSurvival RateChemotherapyHistologyKoreaOvarian cancerSurgerySurvival

Identifiers

PMID29843633
PMCPMC5975501
OpenAlexW2805900528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.